Prostate cancer, the most frequently diagnosed malignancy in men in western countries (Coey, 1993) , is often characterized by elevated prostate-speci®c antigen (PSA) secretion that is broadly used as a blood-borne diagnostic marker of the disease. PSA belongs to a family of kallikreins, consisting of chymotrypsin-like proteins. PSA is synthesized exclusively by normal, hyperplastic and malignant prostate epithelia. Rising PSA levels several fold above background in the blood are indicative of benign prostatic hyperplasia, whereas in end-stage metastatic prostate carcinoma serum concentrations of PSA may be more than a hundred times higher than normal levels of the marker (Kim and Logothetis, 1999; Abate-Shen and Shen, 2000) .
Expression of the PSA gene was demonstrated to be directly regulated by binding of androgen receptor (AR) (Young et al., 1991; Montgomery et al., 1992; Trapman and Cleutjens, 1997) to three androgen responsive elements (AREs) identi®ed within the 5.8 kb PSA promoter (Schuur et al., 1996; Cleutjens et al., 1997; Zhang et al., 1997a) . However, detailed analyses of PSA promoter activity in androgendependent and androgen-independent prostate carcinoma cell lines indicated that the control of transcription of the PSA gene is not limited to androgen regulation (Yeung et al., 2000) .
In the present study we provide evidence indicating the involvement of p53 tumor suppressor in regulation of PSA promoter. The p53 tumor suppressor gene encodes a nuclear transcription factor that accumulates in the cells in response to a variety of stresses inducing growth arrest or apoptosis (Gottlieb and Oren, 1996) . p53 is inactivated in the majority of human tumors, including advanced prostate cancer (Steele et al., 1998; Ozen and Pathak, 2000) . Inactivation of p53 is associated with the loss of the cell cycle checkpoint control, resistance to anti-cancer treatment, genomic instability, and enhanced angiogenesis, leading to rapid tumor progression (Gottlieb and Oren, 1996; Cordon-Cardo et al., 1997) . Many p53-mediated eects are achieved through the activity of p53-responsive genes that are either up-or downregulated by p53. In fact, the activity of p53-responsive genes account, in part, for p53-mediated checkpoint control (waf1, 14-3-3s), apoptosis (bax, genes determining reactive oxygen species metabolism), suppression of angiogenesis (thrompospondins 1 and 2, and VEGF) and p53 feedback regulation (mdm2) (see Gottlieb and Oren, 1996 for references). However, the relationship between changes in gene expression, resulting from p53-de®ciency, and tumor progression is not completely explored.
Mutations of p53 tumor suppressor gene are rare in non-metastatic prostate carcinomas that preserve androgen dependence. Conversely, p53 mutations are frequent at advanced stages of androgen-independent prostate cancer correlating with poor prognosis (Stachhouse et al., 1999; Szende et al., 1999) . Looking for potential targets of p53 regulation associated with advanced stages of the disease we performed microarray hybridization and analyses using a model of LNCaP cells. LNCaP cell line, originally isolated from lymph node metastases of prostate adenocarcinoma, retains wild type p53, androgen dependence and expression of a variety of prostate-speci®c markers, all known as properties of a relatively early stage of prostate cancer progression. Inactivation of p53 function by a dominant negative mutant in these cells imitates an important step in tumor progression and allows analysis of the genetic basis for altered tumor cell phenotype associated with p53 suppression.
A variant of LNCaP cells with inactivated p53, LN-56 (Rokhlin et al., 2000) , was generated by transduction of retroviral construct expressing the potent dominant negative p53 mutant, GSE56 (Ossovskaya et al., 1996) . GSE56-mediated inactivation of p53 resulted in resistance to apoptosis and increased tumorigenicity of LN-56 cells (Rokhlin et al., 2000) , suggesting that p53 is at least partially functional in LNCaP cells. Moreover, both steady-state and inducible expression level of p53-responsive gene p21/ waf1 were reduced in LN-56 cells (Figure 1a ).
Among the genes that showed the most pronounced dierential expression in LNCaP versus LN-56 cells we found PSA, the most broadly used serological diagnostic marker of prostate cancer. It was expressed four times higher in LN-56 than in LNCaP cells. To determine whether dierences in mRNA expression correlate with PSA protein expression, we estimated the amount of secreted PSA in the medium from LNCaP and LN-56 cells and found that the latter cells produced 6 ± 8 times more PSA compared to LNCaP (Figure 1 ). These observations suggested that expression of PSA gene might be under the negative regulatory control of p53 and that elevated expression of PSA in advanced prostate cancer may be indicative for p53 suppression.
To determine whether p53 directly aects transcription from the PSA promoter, we performed a CAT assay in the LNCaP cells transfected with the reporter constructs containing the CAT gene under the control of the proximal PSA promoter (nucleotides 7407 to +11) linked to the PSA enhancer element (nucleotides 75322 to 73740). This construct was previously shown to imitate the endogenous PSA gene regulation (Zhang et al., 1997a,b) . Since PSA transcription is also known to be androgen dependent, for these experiments we used LNCaP cells that retain androgen dependence. To increase the wild type p53 activity, dierent amounts of wild type p53 expression plasmid were co-transfected with the PSA-reporter vector. To inhibit endogenous p53 function, we used co-transfection with the GSE56-expressing plasmid (Ossovskaya et al., 1996) . To monitor the p53 activity in transfected cells, we used another reporter construct containing the CAT reporter gene under the control of p53-responsive promoter carrying the p53-binding site from p21/Waf1 gene.
Introduction of dierent amounts of wild type p53-expressing plasmid into LNCaP cells resulted in dosedependent changes of CAT activity driven from both p21-and PSA-derived promoter elements, though in opposite directions: while the p21 promoter construct was activated, expression of the PSA reporter was suppressed by p53. When GSE56 was co-transfected with either of the reporter constructs, an inverted picture was observed (Figure 2) .
Sequence analysis does not reveal any canonical p53 binding sites within or in the vicinity of the PSA promoter region and in the ®rst intron of the PSA gene. It is noteworthy that most of the known p53-repressed genes also do not possess such sites in their promoter regions and do not necessarily require p53 binding to DNA for repression (Kley et al., 1992; Sun et al., 1999; Xu et al., 2000) .
Since it has previously been shown that negative regulation of transcription by p53 may involve p53-mediated recruitment of histone deacetylases (HDAC) (Murphy et al., 1999) , we tested whether this would be also true for the PSA promoter. Following cotransfection of PSA ± CAT reporter and wild type p53-expressing plasmids, the LNCaP cells were treated with the HDAC inhibitor trichostatin A (TSA) for 24 h and the lysates of transfected cells were tested for CAT activity. These experiments demonstrated that TSA completely abrogated the p53-mediated repression of PSA promoter driven transcriptional activity. At the same time, TSA had no eect on p53-mediated transactivation as determined in a similar experiment employing the p21 promoter-driven CAT reporter construct (Figure 3) . Thus, the PSA gene can be added to a growing list of genes that are negatively regulated by p53 through HDAC-mediated transcriptional repression.
Use of a potent dominant negative p53 inhibitor, GSE56, allowed us to determine the p53 dependence of PSA expression. However, this mutant form does not naturally occur in human tumors. In order to more adequately imitate events naturally occurring in the course of tumor progression, we analysed the eect of four tumor-derived p53 mutants (135Val, 141Ala, 156Pro and 175His), two of which are frequent types of p53 mutants in prostate cancer (141Ala and 175His), on expression of PSA. LNCaP cells were transduced with retroviruses expressing the above p53 mutant variants and the level of PSA was measured in the medium conditioned by each type of the transduced cell populations. In parallel, the potential suppressive eect of the introduced p53 mutants on the activity of endogenous p53 in LNCaP cells was estimated by monitoring the p53-dependent p21 induction in response to doxorubicin treatment (Rokhlin et al., 2000) . As seen in Figure 4 , only one of the tested mutants, 175His, displayed a strong dominant negative activity against the wild type p53 re¯ected by the lack of p21 induction by DNA damage. Val135 mutant showed marginal p53 suppression, while the two remaining mutants did not interfere with p53-mediated p21 induction at all. Remarkably, this pattern of anti-p53 activity was exactly mirrored in the pattern of PSA expression: compared to control, 175His expressing cells produced 9 ± 11 times more PSA, whereas in 135Val cells its level was slightly increased and 141Ala, 156Pro Figure 2 Opposite regulatory eect of p53 on PSA and p21 promoters. Chloramphenicol acetyltransferase (CAT)-reporter constructs were used to estimate p53 in¯uence on PSA and p21 promoter elements. A panel of reporter constructs: pBasic-CAT (CAT gene under minimal thymidine kinase promoter), pWAF1-CAT (p53-binding site from p21/Waf1 gene upstream of the minimal thymidine kinase promoter) (provided by B Vogelstein); p407ECAT plasmid, containing 1.6 kb enhancer (75322 to 73740) and 418 bp promoter (7407 to +11) elements from PSA gene followed by promoterless CAT (provided by CY Young and described by Zhang et al., 1997) were transfected into LNCaP cells in combination with dierent amounts of pLp53SN, containing human wild type p53, pLGSE56SN expressing GSE56 or empty pLXSN vector using Lipofectamin Plus reagent (Gibco BRL). Bars re¯ect relative CAT activity in lysates of LNCaP cells transiently transfected with either PSA ± CAT (upper panel) or p21 ± CAT (lower panel) constructs in combination with the indicated plasmids. Results are normalized according to transfection eciency and CAT expression in control cells transfected with insert-free vector. wt, plasmid expressing wild type human p53 cDNA; GSE, plasmid. (1) and (2) mutants had no detectable eect on PSA. Thus, the dominant negative activity of tumor-derived p53 mutants is well correlated with the increased production of PSA by LNCaP cells, suggesting that similar events may occur during tumor progression.
In conclusion, our study demonstrated that transcription of PSA gene in the prostate carcinoma cell line, LNCaP, is under strict negative control of p53 and its expression can be greatly activated by suppression of wild type p53 activity. Since LNCaP is considered most adequate and conventional among available in vitro models of hormone-dependent prostate cancer, we can presume that the results obtained in these cells may re¯ect regulation of PSA in naturally occurring tumors.
Thus, it appears that one of the most useful diagnostic tumor markers is, in fact, a tissue speci®c indicator of p53 inactivation in prostate cells. Our ®ndings provide a plausible explanation for the frequent increase of PSA levels at advanced stages of prostate cancer associated with poor prognosis and for the heterogenicity of PSA expression within one tumor (Osman et al., 1999) . Although there are no published studies that would be directly focused on a potential link between PSA expression and p53 status of prostate tumors, there are published clinical data, in which a positive relationship between p53 nuclear accumulation and serum PSA levels is highly signi®cant (Quinn et al., 2000) . Being dependent on p53 inactivation, elevated production of PSA may therefore be indicative for the ongoing selection of p53-de®cient cell variants with the broken control of apoptosis, angiogenesis, and genomic stability, all normally regulated by wild type p53. In fact, the loss of functional p53 by LNCaP cells is accompanied not only by elevated PSA secretion but also by acquisition of high tumorigenicity and resistance to TNF (Rokhlin et al., 2000) . ) was prepared in Mo ± MuLV-based retroviral vector pPS ± Hygro, expressing the p53 cDNA under the control of LTR and the hygromycin resistance gene under the control of SV40 promoter (Ossovskaya et al., 1996) . Expression of p53 and p21 proteins was detected in the lysates of untreated LNCaP cell populations by Western immunoblotting with appropriate antibodies. Before loading, samples were normalized according to protein amounts con®rmed by membrane staining and probing with anti-actin antibodies (data not shown). 24-hour medium was collected from the same cell cultures and amounts of PSA protein were measured by Microparticle Enzyme Immunoassay, using IMx operation system (Abbott Diagnostics, Abbott Park, IL, USA)
